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THE immediate influence of the recent developments in nuclear physics upon
the study of cancer is likely to be due to the provision of new and powerful tools
for investigation and of new agents with therapeutic possibilities. It is more
difficult to assess the significance ofthe studies ofthe mechanism ofthe biological
action ofradiations necessitated by the protection of large numbers of industrial
workers from the radio-active hazards involved in making atomic bombs
(R. S. Stone, 1946).
These subjects have been discussed in two previous papers (Mitchell, 1946, a,
b). The present review includes more recent published information, and empha-
sizes different aspects.
The most important technical development is, of course, the chain-reacting
"pile" (Smyth, 1945). This provides a method of preparation of very large
amounts of many radio-active isotopes. It seems likely that these substances
will ultimately become widely applied in medicine and biology as:
1. Tracers for the study of normal and pathological metabolic pro-
cesses and in investigations in pharmacology and therapeutics.
2. Artificial radio-active sources mainly for use in radiotherapy as a
substitute for radium.
3. Agents with therapeutic possibilities such as radio-phosphorus and
the radio-iodines, and probably much better, suitable organic compounds
containing radio-active isotopes, whose action depends on selective con-
centration of the radio-activity in particular cells.
The separation on the industrial scale of non-radio-active isotopes and the
practical development of the mass spectrometer open new possibilities of isotopic
tracer research where radio-active effects are undesirable, as in many clinical
investigations, or where, as in the case ofnitrogen and oxygen, no suitable radio-
active isotopes exist.
The cyclotron still remains an essential instrument both for the production
of small amounts of certain isotopes and as a source of fast neutrons for thera-
peutic trials in cancer and related diseases. It is by no means certain that the
frequency modulated cyclotron will be useful as a therapeutic source of fast
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neutrons, on account of the possibility of reduced neutron output and of the
undesirability of a pulsed output.
A promising field for radiotherapeutic investigation appears to be the study
of high energy, 20-50 Mev. gamma radiation. The newly developed synchrotron
appears to provide a practical source of high energy, e.g. 30 Mev. gamma radia-
tion, much more easily obtainable than the betatron. It is possible that the
linear accelerator may. prove more suitable than the synchrotron. Although
the electron beam can now be extracted from these machines, the therapeutic
possibilities of the high energy beta particles are rather uncertain and must be
investigated with caution.
The development of high energy generators opens the interesting possibility
of the radiotherapeutic application of fast protons of energy in the region of
140 Mev. (Wilson, 1946).
The results of selected investigations are best summarized in the discussion
of these newer agents.
Properties and Production of Isotopes, Radio-active and Stable.
The properties of selected isotopes of especial interest are summarized in
Table I. Recent information on isotopes, which may be useful as radio-active
tracers, and which are produced in the pile, is summarized in Table II. A list
of recent references on isotopes is also given.
The pile is without a rival for producing isotopes in the very large number
of cases where, during irradiation in the pile, a simple slow neutron capture
process occurs, e.g. p31 + n -~ p32, with emission ofgamma radiation. Examples
of specific activities obtainable by n- -yreactions in the pile are for p32 one-
third curie per g. and for S35 10 millicuries per g.
There is one slow neutron (n- p) reaction of especial importance: N14 +
n -> C14 + p. It is of interest that this process is probably responsible for
50-80 per cent of the biological effects of thermal neutrons, the remainder of
the effects being due almost entirely to the n - -y reaction in hydrogen (Mitchell,
1947). However, the n, p reaction in nitrogen is of extreme importance for
isotopic tracer research as the basis for the preparation of C14, the long-lived
radio-active isotope of carbon. It has been shown by Yankwich, Rollefson and
Norris (1946) that the C14 is produced by slow neutron irradiation of compounds
such as ammonium nitrate and urea in the form of very simple compounds
such as C02,CO,CH3OH,H.COOIH, and of especial importance as a starting-point
for organic syntheses, HCN.
In addition to the preparation of materials by direct irradiation, a very
considerable number of radio-active isotopes are found as fission products in
the uranium rods in a pile. A most valuable detailed list of these has been
given by the Plutonium Project (1946).
In general, for the preparation of isotopes the yields with the cyclotron are
very much smaller than those with the pile. A list of isotopes of interest made
with the cyclotron is given in Table IV. The cyclotron can be used to prepare
small amounts of any isotope. Further, the cyclotron is an essential supplement
to the pile in order to produce-
(a) Alternative isotopes not made by slow neutron reactions, e.g.
Na22 (half-life 3-0 years), Fe55 (half-life approximately 4 years).
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(b) Higher concentrations ofactivity where preparation in the cyclotron
involves a change in element and hence chemical separation is possible,
e.g. As74 (half-life 16 days).
(c) Short-lived isotopes, e.g. C" (half-life 20.4 mins.), N13 (half-life
9.93 minutes), F18 (half-life 112 minutes) and 1130 (half-life 12-6 hours),
which is accompanied by smaller amounts of I'sl (half-life 8-0 days).
The methods used in the separation of stable isotopes have been reviewed
by Thode and Reid (1946) and briefly by Urey (1946). The hydrogen isotopes,
H' and H2, have been separated on a large scale by distillation of water and the
exchange reaction between water and hydrogen gas. The carbon isotopes have
been partially separated by thermal diffusion and more cheaply by two chemical
exchange reactions. The nitrogen isotopes have been separated by the exchange
reaction between the ammonium ion in solution and ammonia gas and are now
available commercially in U.S.A. The oxygen isotopes have been concentrated
by distillation of water and by exchange reactions. Sulphur has been separated
by chemical exchange between SO2 and the bisulphite ion. Potassium has
been also separated by chemical exchange methods.
The development of the mass-spectrometer as a practical instrument and
its routine use for hydrocarbon analyses by industrial laboratories in U.S.A.
show clearly the possibility in medicine and biology of non-radio-active isotopic
tracer investigations. From this point of view, although deuterium still has its
uses, the stable isotopes of greatest interest are C13, N15, 018 and S34.
A valuable little book entitled 'Preparation and Measurement of Isotopic
Tracers' (edited by D. Wright Wilson (1946), J. W. Edwards, Ann Arbor),
includes detailed accounts of the mass spectrometer and of the estimation of
C14, in addition to useful information about measurements with Geiger counters.
Isotopic tracers.
The first medical application of radio-active isotopic indicators appears to
have been the investigation by Hevesy (Christiansen, Hevesy and Lomholt,
1924) of the absorption, distribution and excretion of bismuth in connection
with the treatment of syphilis. Since then a surprisingly large literature of
biochemical applications of stable and radio-active tracers has grown up.
Interesting reviews have been published recently by Hevesy (1946) and Ritten-
berg and Shemin (1946).
Probably the most remarkable result ofgeneral biological importance emerging
from tracer studies, mainly by Hevesy and Schoenheimer, is the discovery of
the dynamic state ofthe tissue constituents. Almost all the constituent molecules
of the animal body are continually broken down and resynthesized, so that the
adult living cell is literally in a state of "dynamic equilibrium."
The most important application of tracers in radiotherapeutics so far has
been the work of Hevesy (1945), who used radio-phosphorus (p32)todemonstrate
inhibition of synthesis of thymonucleic acid in normal and tumour cells by
therapeutic doses of X-radiation, and the reality of indirect inhibiting effects
on a second shielded tumour in the same animal. Another relevant application
of p32 is the work of Brues, Tracy and Cohn (1944), who showed that, while the
turnover of thymonucleic acid phosphorus in non-growing liver is extremely
slow, rapid synthesis of thymonucleic acid occurs in regenerative and neoplastic
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TABLE I.-Some Stable and Radio-active Isotopesof Medical
and Biological Interest.
Per cent Energy of radiation
Stability or abundance Type of in Mev.
Element. Isotope. half-life. of stable radiation.
isotope. q Particles. y Rays.
Hydrogen . HI . Stable . 99'98 . .. .
H2 . 0.02 . .
Hs 31 8yr . ... . (3- . 0:015
Carbon Cn 204min. .. + . 0.98
C12 . Stable . 98.9
cis . 1.1 . .. .
C~ .'5000 yr ... 1-'45 ..
Nitrogen N's . 9.93min .. +y 0-92, 1-20 0.28
N14 . Stable . 99.62 .' '
N1r . . 0-38 . .. . ..
N16 . 7-3sec. 0 . .. ±0-5
Oxygen O 0i . 2-1m. . i . (+ . 1-7
016 . Stable . 99-76
017l?9 0-04
018 .. 0-20
019. 31 sec. . :3 . ( .
Fluorine F's 112 min. . + 0-7
F19 . Stable . 100'0 :
Sodium Na" . 3-0 yr. . . . B+, 0-575 1-30
Na"a . Stable 100.0 .'
Na" .1-h. . . (3y . 1-39 .1-38,2'-76
Magnesium Mg" . Stable . 77.4 . .. .
Mg'5 . . 11.-5 . . .
Mg'? . 10'-22 rain .. -,y . 1-8 . 0.64,0-84,
1 02
Phosphorus . p30 . 2-55min . (3+ 3.5 psi. Stable . 100-0 .. .. '
"2 . 14.3days . .. (3 . 1:71
Sulphur 52 Stable . 95.1 . .. .
5"~ . . 420-7 ..4
a5 . 87-Idays 0. . 3- ' · 0-17
S3e . Stable 0016 . ...
Chlorine Cl1a . 33ma .. .. +, . 2-4, 51 ~3 4
C1" . Stable . 754 ¥4
Cl" '-.s10' yr. . (3 . 0-66 ' ' cl-' ~1 6.
Cl'7 . Stable . 24:6 . .6
Cl" . 37min. .. - y 1-1,2-8,5-0 . -65,2-15
Potassium K9 . Stable . 93-38 . .. . .
K40 1.4 x 109 0-012 . y-,y - 1-35 . ~2
yr.
K41 . Stable . 6-61 .
K2 . 12-4hr ... - . 3:5 :NUCLEAR PHYSICS IN CANCER RESEARCH
TABLE I (continued).-Some Stable and Radio-active Isotopes of
Medical and Biological Interest.
Per cent
Stability or abundance
Isotope. half-life. of stable
isotope.
Ca4O
Ca41
Ca42
Ca43
Ca44
Ca45
Ca46
Ca48
Ca49
Fe53
Fes4
Fe55
Fe56
Fe57
Fe58
Fe59
Stable
8 -5 days
Stable
180 days
Stable
2-5 hr.
8 9 min.
Stable
4 yr.
Stable
44ays
44 days
Br79 . Stable
Br80 . 4-4hr.
Br8s . Stable
Br82 . 34 hr.
Br83 . 2 4 hr.
Br84 . 33 min.
96 96
0 64
0-15
2 -06
*. .
00033
0.19
· o
5.9
91.7
2-1
0 3
50-6
49 4
Energy of radiation
Type of in Mev.
radiation. P Ras
, Particles. y Rays.
y
K, y,e-
·.
*.· -,'y
· .
· o
*-,
K, e-
. .
· .
* -,
I.T.e-,y
-,y
0 3
-
·
. 026,03
026 04
. .
0465
1 -0
5'3
1*1
.7
* -
08
(0 006)
1 30, 1 10
0'037
0'547, 0*787,
1 35
.. . 6+ . .. 3+
. -,y . 1-
100 .I ...,-, . 2-02(93%)
1.59 (7%)
. ,-, . 061,1-03
0.595
1 .3
,-1 .35
:
o * .
0 428
0'417, 0'537,
0 667, 0 744
0-367, 0-080
· 0.55 ·1 -6
= negative beta particle emitted from nucleus.
= positive beta particle (positron).
= gamma ray.
= internal conversion electron.
= isomeric transition.
= K-electron capture.
growth. An interesting possible diagnostic application of measurements of p32
in breast tumours in situ has been reported by Low-Beer, Bell, McCorkle, Stone,
Steinbach and Hill (1946).*
The application of p32 as a tracer in metabolic investigations exemplifies the
problems raised by this method of investigation. In order to avoid short-term
effects, it is essential to calculate the dose of radiation received by the tissues
from the radio-active isotope. For example, with p32, one microcurie per g.
* One line of metabolic tracer investigation insufficiently well known is the use of radio-active
brominated compounds, e.g. cholesterol dibromide (Friedman, Solomon and Werthessen, 1939).
Element.
Calcium
Iron
Bromine
Iodine . 1124
1126
1127
1128
1129
1130
131
133
1135
4 40 days
13 days
Stable
250 min.
Very long
12-6 hr.
8 80 days
22 0 hr.
6-7 hr.
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oftissue delivers 43 r. per day, so that for many experiments one must not exceed
tracer doses corresponding to 1/20 microcurie per g. of animal with times of
observation of the order of 6 hours.
Of especial interest is the work of Abels, Kenney, Craver, Marinelli and
Rhoads (1941), who accidentally found significant metabolic changes in the
leucocytes in chronic leukaemias after total body X-radiation with doses as
small as 3 r., as a result of the radiation given by sub-therapeutic doses of p32.
Of much greater importance in the clinical applications of isotopic tracer
research is the avoidance of all possible risk of carcinogenesis as a long-term
result of the radio-active material introduced. In a recent report on the
"Health Protection Activities of the Plutonium Project," Dr. Robert S. Stone
(1946) states that "it is now well established that (radio)strontium given to
mice and rats in amounts insufficient to kill them for many months can cause
bone and lymphatic tissue tumours to develop in significant numbers of animals.
Over long periods of time, plutonium has been shown to cause atrophy
of the bone and bone sarcomas." It is evident that great caution is necessary
before introducing any radio-active materials into human subjects. However,
it is likely that for manyisotopes safe conditions for tracer work will be established
after dosimetric studies and prolonged animal experiments. One factor of
importance is the usually long latent period of carcinogenesis by radiations and
radio-active substances.
Radio-active sources in radiotherapy.
The possibility of practical artificial radio-active sources for use in radio-
therapy has been discussed in the two previous papers (Mitchell, 1946 a and b).
A revised list of isotopes made in the pile and suitable for use as gamma ray
sources in radiotherapy is given in Table III.
The most promising substitute for radium is considered to be radio-cobalt,
Co60, of half-life 5.3 years. The second choice is probably Ta182, of half-life
97 days.
Unseparated fission products contained in uranium metal irradiated in the
pile should be investigated as a possible gamma-ray source. Large amounts of
separated fission products are likely to be available, and those listed in Table III
appear to be perhaps the most suitable.
The gamma radiation from radio-cobalt, Co60, appears to be eminently
suitable for radio-therapeutic application, being approximately monochromatic
and of slightly higher mean energy (1.2 Mev.) than the mean energy of the usual
filtered gamma radiation from radium (approximately 0.8 Mev.). The accom-
panying beta radiation is relatively soft and easily removed by filtration. It
has been calculated by Professor W. V. Mayneord (March 1, 1946-unpublished)
that the dose rate at 1 cm. from a point source of 1 millicurie of Co60° enclosed
in a platinum envelope ofthickness 0 5 mm. is 11-1 r. per hour. However, it may
prove more convenient to measure Co60 sources in terms of equivalent radium.
The production of large amounts of these isotopes by means of the pile raises
the practical possibility of the therapeutic application of large gamma ray
sources-" mass radiation units " equivalent to 50-100 g. of radium.
Of limited therapeutic interest is the possibility of development of beta ray
applicators, using p32 or Sr89. Low-Beer (1946) has published a report on
human skin reactions produced by the external use ofradio-phosphorus, applied
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intheform ofNa2HPO4 solution soaked in blotting-paper and dried. In addition totherapeutic applications, these beta-ray sources may be useful in experimental cancer research, e.g. Stone (1946) states that "it has been established that single large doses of beta rays and multiple small doses can cause cancers in the
skin without the animal being killed by the effect of the beta rays."
Therapeutic possibilities of selectively concentrated radio-active agents.
Radio-active isotope therapy has as yet been limited to inorganic compounds. Radio-phosphorus (p32), and to a much smaller extent the radio-iodines (1130 andI1131), are the only isotopes with which limited clinical trials appear justified without further preliminary animal experiments. In general it seems unlikely that inorganic radio-active isotope therapy will stand the test of time. It seems much more hopeful to study the selective concentration by malignant cells of suitable organic compounds carrying radio-active isotopes of many elements
(Rhoads, 1946). The usual therapeutic applications of p32 in the form of Na2HPO4 appear to depend upon its synthesis into nucleic acids by the multiplying cells. One other method of therapeutic application ofp32 reported (Jones, Wrobel and Lyons, seeLow-Beer, Lawrence and Stone, 1942) depends on the selective concentration ofcolloidal anhydrous chromic phosphate by the cells of the reticulo-endothelial system. It is easy to understand the concentration of the radio-iodines by the thyroid in hyperthyroidism and in the rare cases of carcinoma of the thyroid, where the primary and sometimes also the metastases retain the function of secretion. One must be sceptical ofthe therapeutic possibilities in bone sarcoma of Sr89 or Ca45; it is interesting to note that Stone (1946) reports that radio- "strontium, barium, zirconium, yttrium and others locate quite selectively in
the bones, and many of them stay for long periods of time."
Radio-phosphorus, p32, has been used since 1936 mainly in U.S.A., in the treatment of patients with chronic myeloid and lymphatic leukaemia, poly- cythemia vera, lymphosarcoma and various related diseases (Low-Beer, Lawrence and Stone, 1942; Kenney, 1942; Reinhard, Moore, Bierbaum,
Moore and Kamen, 1946). Lindgren (1944) showed that p32, which is selectively
concentrated, gave better results than Na24, which is not selectively concentrated. The therapeutic possibilities and dosage of radio-phosphorus has been reviewed
recently (Mitchell, 1947b). It is considered that the present position with regard
to its therapeutic applications may be summarized as follows:
1. In the treatment of chronic myeloid and chronic lymphatic
leukaemia, p32 is probably as satisfactory as, but no better than X-radia-
tion. It is important to investigate the possibility of development of
methods of routine treatment of these diseases by means of p32. On
the average, each case is likely to require 10 to 15 millicuries of p32 given,
preferably intravenously, in the form of a solution of Na2HPO4 in fractions
in an over-all time of 10-12 weeks. It is desirable to correlate the dose
with roentgen units (Marinelli, 1942), and to measure the differential
absorption ratio in different tissues (Kenney, Marinelli and Woodard,
1941). The greatest risk to be avoided is bone marrow damage.
2. Radio-phosphorus is stated to be the treatment of choice in poly-
cythaemia vera, but even here its action may be too slow, and ancillary
venesection frequently required.
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3. It seems likely that the only other disease, or group of diseases, in
which the therapeutic possibilities of p32 administered internally should
be investigated, is lymphosarcoma.
One interesting aspect ofthe present position is that, while cases ofHodgkin's
disease do not respond as favourably to p32 as to X-radiation, promising results
are being obtained in this condition, perhaps especially in the radio-resistant
stages with the "nitrogen mustards." (References-General.)
The therapeutic possibilities of the radio-iodines must be-considered with
great caution. A considerable number of clinical trials have been carried out
in the U.S.A. This work has been reviewed by Leucutia (1946). It is evident
from the recent papers of Hertz and Roberts (1946), and Chapman and Evans
(1946), that selected cases of hyperthyroidism may respond satisfactorily to
radio-iodine therapy. However, it seems that as yet there is insufficient evidence
as to dosage and long-term effects of the radio-iodines to exclude with certainty
the possibility under some conditions of late carcinogenesis. There is also the
further question of possible renal damage by the excreted radio-iodine. Until
further information on these subjects is available, it is probably wise to restrict
clinical therapeutic trials of the radio-iodines to the much more difficult problem
of carcinoma of the thyroid.
Only a very small proportion of all cancers of the thyroid retain the function
ofiodine concentration; ofthese only a few concentrate radio-iodines sufficiently
to deliver therapeutically effective doses. However, there are the extremely
rare cases of carcinoma of the thyroid, where functional secretion is a striking
feature of both the primary and metastases, and where dramatic results can be
obtained by radio-iodine therapy (Seidlin, Marinelli and Oshry, 1946). Accord-
ingly the present position appears to be that there is only a very limited field for
clinical trials of the therapeutic possibilities of the radio-iodines.
Therapeutic applications of high energy beta and gamma radiations.
Considerable progress in the development of high energy generators has
taken place recently since the previous short review (Mitchell, 1946a), which
this paragraph supplements.
The synchrotron has been developed as a practical instrument (Goward and
Barnes, 1946), and should become available in this country as a source of gamma
radiation of energy up to 30 Mev. for dosimetric and biological investigations,
and subsequent clinical trials in the treatment of deeply situated malignant
tumours. A large number of papers have recently appeared on the theory of
the synchrotron, e.g. Bohm and Foldy, 1946. The synchrotron can be operated
initially as a betatron until the electrons have reached an energy of perhaps
1-5 Mev., when the dee voltage is turned on and the machine works as a synchro-
tron for the rest ofthe acceleration.
Kerst and his collaborators (Skaggs, Almy, Kerst and Lanzl, 1946) have
succeeded in extracting the electron beam from the betatron, but the therapeutic
possibilities of these high energy beta particles are rather uncertain.
It now appears likely that there will be very little therapeutic superiority of
the high energy gamma radiation from a betatron or synchrotron operated at
50 Mev. over that for 20 Mev. Probably the highest energy required for clinical
therapeutic trials will be provided by an instrument working up to 30 Mev.
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SUMMARY.
This review summarizes recent information on the following subjects:
1. Properties and production of isotopes of interest, mainly radio-active,
with Tables.
2. Isotopic tracer research, with precautions necessary, including avoidance
of risk of carcinogenesis in possible clinical applications.
3. Artificial radio-active sources for use in radiotherapy made by means of
the pile (see Table III). The most promising substitute for radium appears to
be radio-cobalt, Co60, of half-life 5-3 years. Unseparated fission products should
be investigated as an alternative.
4. Therapeutic possibilities of selectively concentrated radio-active agents,
including the present position with regard to therapeutic applications of radio-
phosphorus and the radio-iodines.
5. Therapeutic application of high energy (30 Mev.) gamma radiation and
the development of the synchrotron.
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